Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2

Journal of Clinical Investigation

Volumn 99, Issue 10, 1997, Pages 2509-2517

  Yoneda, Toshiyuki ^a,d   Sasaki, Akira ^a   Dunstan, Colin ^a   Williams, Paul J ^b   Bauss, Frieder ^c   De Clerck, Yves A ^a   Mundy, Gregory R ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

^d OKAYAMA UNIVERSITY   (Japan)

Author keywords

bone metastasis; breast cancer; ibandronate; osteoclast; TIMP 2

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; GELATINASE A; GELATINASE INHIBITOR; HYGROMYCIN B; IBANDRONIC ACID; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; BREAST CARCINOMA; CANCER INVASION; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030927205     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119435     Document Type: Article

References (42)

1. Fidler, I.J. 1990. Critical factors in the biology of human cancer metastasis. Cancer Res. 50:6130-6138.
2. Ruoslahti, E. 1996. How cancer spreads. Sci. Am. 275:72-77.
3. Rusciano, D., and M.M. Burger. 1994. Why do cancer cells metastasize inio particular organs. Bio. Essays. 14:185-193.
4. Fidler, I.J. 1995. Modulation of the organ microenvironment for treatment of cancer metastasis. J. Natl. Cancer Inst. 87:1588-1592.
5. Cifuentes, N., and J.W. Pickren. 1979. Metastases from carcinoma of mammary gland: an autopsy study. J. Surg. Oncol. 11:193-205.
6. Coleman, R.E., and R.D. Rubens. 1987. The clinical course of bone metastases from breast cancer. Br. J. Cancer. 55:61-66.
7. Yoneda, T., A. Sasaki, and G.R. Mundy. 1994. Osteolytic bone disease in breast cancer. Breast Cancer Res. Treat. 32:73-84.
8. Yoneda, T. 1996. Mechanisms of preferential metastasis of breast cancer to bone. Int. J. Oncol. 9:103-109.
9. Lewin, D.I. 1996. Evolutions: metastasis. J. NIH. Res. 8:85-87.
10. Takeichi, M. 1993. Cadherins in cancer: implications for invasion and metastasis. Curr. Opin. Cell. Biol. 5:806-811.
11. Mbalaviele, G., C.R. Dunstan, A. Sasaki, P.J. Williams, G.R. Mundy, and T. Yoneda. 1996. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. Cancer Res. 56:4063-4070.
12. Guise, T.A., J.J. Yin, S.D. Taylor, Y. Kumagai, M. Dallas, B.F. Boyce, T. Yoneda, and G.R. Mundy. 1996. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J. Clin. Invest. 98:1544-1549.
13. Sasaki, A., B.F. Boyce, B. Story, K.R. Wright, M. Chapman, R. Boyce, G.R. Mundy, and T. Yoneda. 1995. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 55:3551-3557.
14. Muhlbauer, R.C., F. Bauss, R. Schenk, J. Janner, E. Bosies, K. Strein, and H. Fleisch. 1991. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J. Bone Min. Res. 6:1003-1011.
15. Cailleau, R., R. Young, M. Olive, and W.J. Reeves. 1974. Breast tumor cell lines from pleural effusions. J. Natl. Cancer Inst. 53:661-674.
16. DeClerck, Y.A., N. Ferez, H. Shimada, T.C. Boone, K.E. Langley, and S.M. Taylor. 1992. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res. 52:701-708.
17. Yoneda, T., T.B. Aufdemorte, R. Nishimura, N. Nishikawa, M. Sakuda, M.M. Alsina, J.B. Chavez, and G.R. Mundy. 1991. Occurrence of hypercalcemia and leukocytosis with cachexia in a human squamous cell of the maxilla in athymic nude mice. A novel experimental model of 3 concomitant paraneoplastic syndromes. J. Clin. Oncol. 9:468-477.
18. Nakai, M., G.R. Mundy, P.J. Williams, B. Boyce, and T. Yoneda. 1992. A synthetic antagonist to laminin inhibits the formation of osleolytic metastases by human melanoma cells in nude mice. Cancer Res. 52:5395-5399.
19. Arteaga, C.L., S.D. Hurd, A.R. Winnier, M.D. Johnson, B.M. Fendly, and J.T. Forbes. 1993. Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-β interactions in human breast cancer progression. J. Clin. Invest. 92:2569-2576.
20. Price, J.E., A. Polyzos, R.D. Zhang, and L.M. Daniels. 1990. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res. 50:717-721.
21. Manicourt, D.H., and V. Lefebvre. 1993. As assay for matrix metalloproteinases and other proteases acting on proteoglycans, casein, or gelatin. Anal. Biochem. 215:171-179.
22. Kleiner, D.E., E.J. Unsworth, H.C. Krutzsch, and W.G. Stetler-Stevenson. 1992. Higher-order complex formation between the 72-kilodalton type IV collagenase and tissue inhibitor of metalloproteinases-2. Biochemistry. 31:1665-1672.
23. Fridman, R., R.E. Bird, M. Hoyhtya, M. Oelkuct, D. Komarek, C.M. Llang, M.L. Berman, L.A. Liotta, W.G. Stetler-Stevenson, and T.R. Fuerst. 1993. Expression of human recombinant 72 kDa gelatinase and tissue inhibitor of metalloproteinase-2 (TIMP-2): characterization of complex and free enzyme. Biochem. J. 289:411-416.
24. Okada T., H. Okuno, and Y. Mitsui. 1994. A novel in vitro assay system for transendothelial tumor cell invasion: significance of E-selectin and α1 integrin in the transendothelial invasion by HT1080 fibrosarcoma cells. Clin. & Exp. Metastasis. 12:305-314.
25. Okada, T., and R.G. Hawley. 1995. Adhesion molecules involved in the binding of murine myeloma cells to bone marrow stromal elements. Int. J. Cancer. 63:823-830.
26. Globus, R.K., J. Plouet, and D. Gospodarowicz. 1989. Cultured bovine bone cells synthesize basic fibroblast growth factor and store it in their extracellular matrix. Endocrinology. 124:1539-1547.
27. Ray, K.M., and W.G. Stetler-Stevenson. 1995. Gelatinase A activity directly modulates melanoma cell adhesion and spreading. EMBO J. 14:908-917.
28. Hayakawa, T., K. Yamashita, E. Ohuchi, and A. Shinagawa. 1994. Cell growth-promoting activity of tissue inhibitor of metalloproteinasaes-2 (TIMP-2). J. Cell Sci. 107:2373-2379.
29. Montgomery, A.M.P., B.M. Mueller, R.A. Reisfeld, S.M. Taylor, and Y.A. DeClerck. 1994. Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res. 54:5467-5473.
30. Koop, S., R. Khokha, E.E. Schmidt, I.C. MacDonald, V.L. Morris, A.F. Chambers and A.C. Groom. 1994. Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res. 54:4791-4797.
31. De Bruyn, P.P.H., S. Michelson, and T.B. Thomas. 1971. The migration of blood cells of the bone marrow through the sinusoidal wall. J. Morph. 133: 417-438.
32. Wingo, P.A., T. Tong, and S. Bolden. 1995. Cancer statistics, 1995. CA Cancer J. Clin. 45:8-30.
33. MacDougall, J.R., and L.M. Matrisian. 1995. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev. 14:351-362.
34. r 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res. 53:140-146.
35. Polette, M., C. Clavel, M. Cockett, S.G. de Bentzmann, G. Murphy, and P. Biremhaut. 1993. Detection and localization of mRNAs encoding matrix metalloproteinases and their tissue inhibitor in human breast pathology. Invasion & Metastasis. 13:31-37.
36. Sledge, W.G., M. Qulali, R. Goulet, E.A. Bone, and R. Fife. 1995. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J. Natl. Cancer Inst. 87:1546-1550.
37. Azzam, H.S., G. Arand, M.E. Lippman, and E.W. Thompson. 1993. Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J. Natl. Cancer Inst. 85:1758-1764.
38. Blavier, L., and J.M. Delaisse. 1995. Matrix metalloproteinases are obligatory for the migration of preosteoclasts to the developing marrow cavity of primitive long bones. J. Cell Sci. 108:3649-3659.
39. Okada, Y., K. Naka, K. Kawamura, T. Matsumoto, I. Nakanishi, N. Fujimoto, H. Sato, and M. Seiki. 1995. Localization of matrix metalloproteinase 9 (92-kilodalton gelatinase/Type IV collagenase=gelatinase B) in osteoclasts: implications for bone resorption. Lab. Invest. 72:311-322.
40. Witty, J.P., S.A. Foster, P. Stricklin, L.M. Matrisian, and P.H. Stern. 1996. Parathyroid hormone-induced resorption in fetal rat limb bones is associated with production of the metalloproteinases collagenase and gelatinase B. J. Bone Min. Res. 11:72-78.
41. Hill P.A., J.J. Reynolds, and M.C. Meikle. 1993. Inhibition of stimulated bone resorption in vitro by TIMP-1 and TIMP-2. Biochim. Biophys. Acta. 1177: 71-74.
42. Hortobagyi, G.N., R.L. Theriault, L. Porter, D. Blayney, A. Lipton, C. Sinoff, H. Wheeler, J.F. Simeone, J. Seaman, R.D. Knight, M. Heffernan, and D.J. Reitsma. 1996. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. W. Engl. J. Med. 335: 1785-1791.